HIV resistance testing in the USA - A model for the application of pharmacogenomics in the clinical setting

Pharmacogenomics

Volumn 6, Issue 2, 2005, Pages 169-179

  Blum, Ronald A ^a   Wylie, Neil ^a   England, Tom ^a   French, Cynthia ^a  

^a Specialty Laboratories   (United States)

Author keywords

Genotyping; HIV; Laboratory testing; Pharmacogenomics; Reimbursement; Resistance

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROFECOXIB; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ASSAY; BIOLOGICAL MODEL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISEASE COURSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG WITHDRAWAL; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; NONHUMAN; PHARMACOGENOMICS; PHENOTYPE; PREVALENCE; REVIEW; SURVIVAL; TREATMENT FAILURE; UNITED STATES; VIRAL GENETICS; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOMICS; GENOTYPE; HIV-1; HLA ANTIGENS; HUMANS; PHARMACOGENETICS; UNITED STATES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 18144363537     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.6.2.169     Document Type: Review

References (53)

1. Payne DA, Bryant BJ, for the AACC Pharmacogenomics Committee: HIV Pharmacogenomics: closer to personalized therapy? Am. J. Pharmacogenomics 4(3), 141-150 (2004).
2. Holgate ST. Pharmacogenetics: the new science of personalizing treatment. Curr. Opin. Allergy Clin. Immunol 4, 37-38 (2004).
3. Valdes R Jr, Linder MW: Fine-tuning pharmacogenomics: paradigm for linking laboratory results to clinical action. Clin. Chem. 50(9), 1498-1499 (2004).
4. McLeod HL, Siva C: The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 3, 89-98 (2002).
5. Nolte FS: Hepatitis C virus genotyping: clinical implications and methods. Mol. Diagn. 6, 265-277 (2001).
6. Hirsch MS, Brun-Vezinet F, Clotet B et al.: Questions to and answers from the International AIDS Society-USA resistance testing guidelines panel. Top. HIV Med. 11(4), 150-154 (2003).
7. Hirsch MS, Brun-Vezinet F, Clotet B et al.: Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus Type 1: 2003 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 37, 113-128 (2003).
8. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) (2003).
9. Vandamme A-M, Sonnerborg A, Ait-Khaled M et al.: Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir. Ther. 9(6), 829-848 (2004).
10. Wegner SA, Wallace MR, Aronson NE et al.: Long-term efficacy of routine access to antiretroviral-resistance testing in HIV Type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin. Infect. Dis. 38, 723-730 (2004).
11. Weinstein MC, Goldie SJ, Losina E et al.: Use of genotypic resistance testing to guide HIV therapy: clinical impact and costeffectiveness. Ann. Intern. Med. 134(6), 440-450 (2001).
12. Corzillius M, Muhlberger N, Sroczynski G, Jaeger H, Wasem J, Siebert U: Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV. Antiviral. Ther. 9(1), 27-36 (2004).
13. Dunn DT, Gibb DM, Babiker AG, Green H, Darbyshire JH, Weller IVD: HIV drug resistance testing: is the evidence rally there? Antirvir. Ther. 9, 641-648 (2004).
14. Grimsley G: Human immunodeficiency viruses. In: Use and Interpretation of Laboratory Tests in Infectious Disease (9th edn). Specialty Laboratories, Inc., Santa Monica, CA, USA 137-146 (2004).
15. CDC L285 Slide Series-Mortality, Slide 3. Comparison of mortality data from AIDS case reports and death certificates according to ICD-9 and ICD-10 rules for selecting the underlying cause of death, USA, 1987-2000.
16. Walker BD: Immunopathogenesis and immune response in HIV infection. Medscape (June 12, 2003).
17. Carrington M, O'Brien SJ: The influence of HLA genotyping on AIDS. Ann. Rev. Med. 54, 535-551 (2003).
18. Christiansen FT, Gaudieri S, Santis DD et al.: NK receptor genes are predictors of HIV progression. Hum. Immunol. 64(Suppl.), S12 (2003).
19. Mallal S, Nolan D, Witt C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 59(9308), 727-732 (2002).
20. Nolan D, Gaudier S, Mina J, Mallal S: Impact of host genetics on HIV disease progression and treatment: new conflicts on an ancient battlefield. AIDS 18, 1231-124 (2004).
21. MacArthur RD: Drug resistance: an updated guide to genotype interpretation. AIDS Read. 14, 256-266 (2004).
22. + T-cell demographics and dynamics in lymphatic tissues. Ann. Rev. Immunol. 17, 625-656 (1999).
23. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 271, 1582-1586 (1996).
24. Bebenek K, Abbotts J, Roberts JD, Wilson SH, Kunkel TA: Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. J. Biol. Chem. 264, 16948-16956 (1989).
25. Barbour JD, Wrin T, Grant RM et al.: Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J. Virol. 76, 11104-11112 (2002).
26. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D: Impaired fitness of human immunodeficiency virus Type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71, 1089-1096 (1997).
27. Perez-Olmeda M, Rubio A, Puig T et al.: Evolution of genotypic resistance to nucleoside analogues in patients receiving protease inhibitor-containing regimens. Antivir. Ther. 4(3), 179-181 (1999).
28. Volberding PA: HIV therapy in 2003: consensus and controversy. AIDS 17(Suppl. 1), S4-S11 (2003).
29. Richman DD, Morton SC, Wrin T et al.: The prevalence of antiretroviral drug resistance in the United States. AIDS 18, 1393-1401 (2004).
30. Eron JJ Jr: The role of resistance testing in treatment-naive HIV-infected individuals. Resistance testing in HIV: an in-depth series. iMedOptions (2004).
31. Yeni PG, Hammer SM, Carpenter CC et al.: Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288(2), 222-235 (2002).
32. EuroGuidelines Group for HIV Resistance: Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGuidelines Group for HIV resistance. AIDS 15(3), 309-320 (2001).
33. BHIVA Writing Committee, BHIVA Executive Committee: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2(4), 276-313 (2001).
34. Dam E, Clavel F, Calvez V et al.: Comparison of HIV-1 resistance phenotype obtained by two different assay systems. 5th International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, USA (2001).
35. Miller V, Schuurman R, Clavel F et al.: (EuroGuidelines Group). Comparison of HIV-1 drug susceptibility (phenotype) results reported by three major laboratories. 5th International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, USA (2001).
36. Kuiken C, Korber B, Shafer RW et al.: HIV sequence databases. AIDS Rev. 5, 52-61 (2003).
37. Lamers S, Beason S, Dunlap L, Compton R, Salemi M: HIVbase: a PC/Windows-based software offering storage and querying power for locally held HIV-1 genetic, experimental and clinical data. Bioinformatics 20(3), 436-438 (2004).
38. Chen L, Perlina A, Lee CJ: Positive selection detection in 40,000 human immunodeficiency virus (HIV) Type 1 sequences automatically identifies drug resistance and positive fitness mutations in HIV protease and reverse transcriptase. J. Virol. 78(7), 3722-3732 (2004).
39. Saag MS: HIV resistance testing in clinical practice: a QALY-fied success. Ann. Intern. Med. 134, 475-7 (2001) (Editorial).
40. Kelleher AD, Long C, Holmes EC et al.: Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193, 375-386 (2001).
41. Tang J, Tang S, Lobashevsky E et al.: Favorable and unfavorable HLA class I alleles and hapotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1. J. Virol. 76, 8276-8284 (2002).
42. Tang J, Wilson CM, Meleth S et al.: Host genetic profiles predict virol and immunological control of HIV-1 infection in adolescents. AIDS 16, 2275-2284 (2002).
43. Carrington M, Nelson GW, Martin MP et al.: HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283, 1748-1752 (1999).
44. Kaloterakis A, Papasterides C, Filiotou A, Economidou I, Hadjiyannis S, Stratigos J: HLA in familial and non-familial Kaposi's sarcoma. Tissue Antigens 23, 240-245 (1984).
45. Carrington M, Dean M, Martin MP, O'Brien SJ: Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum. Mol. Genet. 8, 1939-1945 (1999).
46. An P, Nelson GW, Wang L et al.: Modulating influence on HIV/AIDS by interact RANTES gene variants. Proc. Natl Acad. Sci. USA 99, 10002-10007 (2002).
47. O'Brien SJ, Moore JP: The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol. Rev. 177, 99-111 (2000).
48. Gonzalez E, Rovin BH, Sen L et al.: HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc. Natl Acad. Sci. USA 99, 13795-13800 (2002).
49. Gonzalez E, Kulkarni H, Bolivar H et al.: The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. ScienceExpress.org (January 6, 2005).
50. Shin HD, Winkler c, Stevens JC et al.: Genetic restriction of HIV-1 pathogenes AIDS by promoter alleles of IL10. Proc. Natl Acad. Sci. USA 97, 14467-14472 (2000).
51. Nakayama EE, Meyer L, Iwamoto A et al.: Protective effect of interleukin-4-58 polymorphism on human immunodeficiency virus type 1 disease progression: relationship with virus load. J. Infect. Dis. 185, 1183-1186 (2002).
52. Martin MP, Gao X, Lee JH et al.: Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31, 429-434 (2002).
53. Wilson JW: Update on antiretroviral drug resistance testing: combining laboratory technology with patient care. AIDS Read. 13(11), 25-38 (2003).